Research Article Details
| Article ID: | A18284 |
| PMID: | 31239898 |
| Source: | Acad Forensic Pathol |
| Title: | Liver Pathology in First Presentation Diabetic Ketoacidosis at Autopsy. |
| Abstract: | Diabetes mellitus is an enormous health burden on developed and developing nations. Eight percent of people in the United States are stated to have diabetes mellitus and 79 million people have impaired glucose tolerance. Sudden death from diabetic ketoacidosis (DKA) is common and nonalcoholic fatty liver disease (NAFLD) is a frequent finding in patients with diabetes mellitus and impaired glucose tolerance. Diabetic ketoacidosis accounts for around 1% of autopsy cases in our units and 25% of these cases did not have a previous diagnosis of diabetes mellitus. We have analyzed for the presence of NAFLD in 16 patients dying on first presentation of DKA. Some degree of NAFLD was present in all cases, with all but one case having some degree of steatosis and some degree of fibrosis was present in 14 out of 16 cases, though none where cirrhotic. Inflammation was present in nine of 13 cases and glyogenated nuclei in five of 13 cases. NAFLD can be well established in patients dying of DKA who were not known to be diabetic before death. The pathology shares features with alcoholic liver disease. They should not be mistakenly diagnosed as dying of other causes of ketoacidosis based upon the liver pathology present. |
| DOI: | 10.23907/2016.028 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|